Compare KIDS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | ASMB |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.4M | 512.1M |
| IPO Year | 2016 | 2010 |
| Metric | KIDS | ASMB |
|---|---|---|
| Price | $20.88 | $26.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $24.67 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 141.9K | 140.4K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.42 | $18.50 |
| 52 Week High | $22.80 | $39.71 |
| Indicator | KIDS | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 62.17 | 45.20 |
| Support Level | $15.66 | $21.80 |
| Resistance Level | $21.40 | $30.36 |
| Average True Range (ATR) | 0.97 | 1.30 |
| MACD | 0.09 | -0.12 |
| Stochastic Oscillator | 82.23 | 18.77 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.